白血病治療薬の世界市場:慢性リンパ性白血病、急性リンパ性白血病、急性骨髄性白血病、慢性骨髄性白血病

◆英語タイトル:Global Leukemia Therapeutics Market 2016-2020
◆商品コード:IRTNTR10286
◆発行会社(調査会社):Technavio
◆発行日:2016年9月20日
◆ページ数:110
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、白血病治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、白血病治療薬の世界市場規模及び予測、疾患種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Leukemia
Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid.

Technavio’s analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemias.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Leukemia Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• F. Hoffmann-La Roche
• Novartis
• Bristol-Myers Squibb
• AbbVie
• Teva Pharmaceuticals

[Other prominent vendors]
• Altor BioScience
• Amgen
• ARIAD Pharmaceuticals
• Arno Therapeutics
• Astex Pharmaceuticals
• AstraZeneca
• Baxter Healthcare
• Bayer HealthCare
• Bellicum Pharmaceuticals
• Biogen
• Boehringer Ingelheim
• BioLineRx
• Boston Biomedical
• Celator Pharmaceuticals
• Celgene
• CTI BioPharma
• Chroma Therapeutics
• Chugai Pharmaceutical
• Cyclacel Pharmaceuticals
• Daiichi Sankyo
• Eisai
• Emergent BioSolutions
• Erytech Pharma
• Fate Therapeutics
• Genzyme
• Gilead Sciences
• GlaxoSmithKline
• iDD biotech
• Immune Pharmaceuticals
• Immunomedics
• Infinity Pharmaceuticals
• Innate Pharma
• Jazz Pharmaceuticals
• Juno Therapeutics
• Karyopharm Therapeutics
• Ligand Pharmaceuticals
• MEDA Pharmaceuticals
• MedImmune
• Merck
• Midas Pharma
• Molecular Templates
• MorphoSys
• Nippon Shinyaku
• Novo Nordisk
• Onconova Therapeutics
• Ono Pharmaceuticals
• Orphan Europe
• Otsuka
• Pfizer
• Portola Pharmaceuticals
• Regeneron Pharmaceuticals
• Sanofi
• Sigma-Tau Pharmaceuticals
• Stemline Therapeutics
• Sunesis Pharmaceuticals
• TG Therapeutics
• TheraMAB
• Tolero Pharmaceuticals
• XEME Biopharma
• Xencor
• ZIOPHARM Oncology

[Market driver]
• Technological advances in the monitoring of leukemia
• For a full, detailed list, view our report

[Market challenge]
• Limitations associated with current therapeutic options
• For a full, detailed list, view our report

[Market trend]
• Rise in the development of combination therapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation by disease type

PART 08: Global CLL therapeutics market
• Market overview
• Total addressable market for global CLL therapeutics
• Vendors in the market

PART 09: Global ALL therapeutics market
• Market overview
• Vendors in the market

PART 10: Global AML therapeutics market
• Market overview
• Vendors in the market

PART 11: Global CML therapeutics market
• Market overview
• Vendors in the market

PART 12: Geographical segmentation
• Global leukemia therapeutics market by geography 2015-2020
• Leukemia therapeutics market in Americas
• Leukemia therapeutics market in EMEA
• Leukemia therapeutics market in APAC

PART 13: Market drivers
• Special regulatory designations for drugs
• Technological advances in the monitoring of leukemia
• Application for expanded indication approvals

PART 14: Impact of drivers

PART 15: Market challenges
• Complicated disease prognosis
• Financial and infrastructural constraints
• Limitations associated with current therapeutic options
• Delay in diagnosis

PART 16: Impact of drivers and challenges

PART 17: Market trends
• Rise in the development of combination therapies
• Patient assistance programs
• Focus on the identification of targets for the development of new therapies

PART 18: Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 19: Key vendor analysis
• F. Hoffmann-La Roche
• Novartis
• Bristol-Myers Squibb
• AbbVie
• Teva Pharmaceuticals

PART 20: Appendix
• List of abbreviations

PART 21: Explore Technavio



【掲載企業】

F. Hoffmann-La Roche, Novartis, Bristol-Myers Squibb, AbbVie, Teva Pharmaceuticals, Altor BioScience, Amgen, ARIAD Pharmaceuticals, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Bellicum Pharmaceuticals, Biogen, Boehringer Ingelheim, BioLineRx, Boston Biomedical, Celator Pharmaceuticals, Celgene, CTI BioPharma, Chroma Therapeutics, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Daiichi Sankyo, Eisai, Emergent BioSolutions, Erytech Pharma, Fate Therapeutics, Genzyme, Gilead Sciences, GlaxoSmithKline, iDD biotech, Immune Pharmaceuticals, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Ligand Pharmaceuticals, MEDA Pharmaceuticals, MedImmune, Merck, Midas Pharma, Molecular Templates, MorphoSys, Nippon Shinyaku, Novo Nordisk, Onconova Therapeutics, Ono Pharmaceuticals, Orphan Europe, Otsuka, Pfizer, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals, Stemline Therapeutics, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, Tolero Pharmaceuticals, XEME Biopharma, Xencor, and ZIOPHARM Oncology.

【レポートのキーワード】

白血病治療薬、慢性リンパ性白血病薬、急性リンパ性白血病薬、急性骨髄性白血病薬、慢性骨髄性白血病薬、白血病、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[白血病治療薬の世界市場:慢性リンパ性白血病、急性リンパ性白血病、急性骨髄性白血病、慢性骨髄性白血病]販売に関する免責事項
★調査レポート[白血病治療薬の世界市場:慢性リンパ性白血病、急性リンパ性白血病、急性骨髄性白血病、慢性骨髄性白血病]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆